Ask the Expert: Psuedo Progression (GBM)

What is Pseudo-Progression Following Treatment for Glioblastoma Multiforme?

Glioblastoma Multiforme (GBM) is a rapidly dividing brain tumor. The current standard of care for newly diagnosed GBM is 6 weeks of radiotherapy with concurrent temozolomide (RT/TMZ) followed by maintenance monthly temozolomide for 6 months up to 1 year. The addition of temozolomide is a major advance in the treatment of GBM with improved patient overall survival as compared to radiation alone.

As RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ. One phenomena, termed Pseudo-Progression (psPD), has become more apparent with the use of this more efficacious treatment approach as compared to radiation alone. Essentially psPD refers to post-treatment imaging changes in the tumor, where the tumor appears larger and/or brighter from greater contrast uptake as compared to the pre-treatment baseline CT or MRI image. These changes may mislead the patient and the doctor in thinking the tumor is getting worse due to true progression when in fact these changes are transient. In true psPD, eventually the tumor stabilizes or even shrinks as opposed to further growth if true progression. It is important to also realize that the increase in tumor size may accompany a worsening in the patient’s symptoms and these also either stabilize or resolve in the psPD situation.

Recent data reported by Sanghera, Perry, Sahgal et al. from the Sunnybrook Health Sciences Odette Cancer Centre reports that in the 26% percent of patients suspected of early true progression (defined as progression during radiation or within 8 weeks of completing RT/TMZ), a psPD rate of 32% was determined (in press, Canadian Journal of Neuroscience). Strict imaging criteria (RECIST) were used to ensure uniform analysis and a strength of the study. In terms of symptoms that accompanied imaging changes, 60% of patients also had clinical symptoms suggestive of true progression, however, in each case of psPD symptoms resolved with time. Patients with psPD were also found to have a better overall survival, and this has also been reported by other investigators. The rationale is that these patients may have favorable genetics to temozolomide response with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. Therefore, the enhanced response reflects the tumors biology to be more susceptible to treatment effect, and these patients live longer.

There are significant clinical impacts for patients with psPD with the RT/TMZ regimen. If a patient is thought to have true progression as opposed to psPD then several actions may be taken that would not be beneficial to the patient such as; the adjuvant schedule of TMZ may be discontinued; patients may be relegated to hospice with the notion that the disease is treatment resistant; or may be enrolled into clinical trials with an actual better prognosis as compared to patients with true progression and the resolution of the clinical and or radiological worsening falsely deemed secondary to further treatment versus the natural history of psPD. Therefore, clinicians have to be aware of this phenomena and judge the patient's clinical status to either follow-up with MRI imaging at a shorter frequency to see if clinical and imaging changes resolve or stabilize, or initiate alternative therapeutic approaches assuming the patient to be truly progressing. It certainly is a difficult situation that we need to learn more about in order to treat patients effectively and appropriately.

You can download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf).
A special thank you to Dr. Arjun Sahgal, Department of Radiation Oncology at Sunnybrook Odette Cancer Centre and the Princess Margaret Hospital and Dr. Normand J. Laperriere, Department of Radiation Oncology at Princess Margaret Hospital for taking the time to answer this important question. Both Dr. Sahgal and Dr. Laperriere volunteer for Brain Tumour Foundation of Canada as members of the Professional Advisory Group.
 

Return to Information Sheets here.

Share This

Featured Story

Mya's Story "Just try to relax and be brave"

Bringing hope to children and families in the brain tumour community is important to Mya and Brooke. It’s been a tough couple of years for both the girls, and they have words of wisdom to share with anyone else that faces the brain tumour journey. “Don’t think about whatever’s happening. Just try to relax and be brave,” says Mya. “And if they’re watching their brother or sister go into surgery, I’d tell them be brave and be strong, too,” adds Brooke.

Learn more

Spotlight

Five brain tumour survivors are following their dreams thanks to you!

...

Learn more

What does 'patient experience' mean?

This September, Brain Tumour Foundation of Canada CEO Carl Cadogan is chairing the Second Annual National Forum on Patient Experience....

Learn more

Upcoming Events

  • 17/Sep/2014: Windsor Support Group: Learn more >
  • 17/Sep/2014: Calgary Support Group: Meets at Wellspring Calgary, 1404 Home Road NW, Calgary, Alberta, T3B 1G7... Learn more >
  • 17/Sep/2014: Niagara Region Support Group: Meets at Wellspring Niagara, 3250 Schmon Parkway, Thorold, ON, L2V 4Y6... Learn more >
  • 17/Sep/2014: Winnipeg Support Group: Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2014 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
Imagine Canada Ethical Code